Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib

Archives of Ophthalmology

Volumn 127, Issue 4, 2009, Pages 494-499

  Takahashi, Kyoichi ^a   Saishin, Yoshitsugu ^a   Saishin, Yumiko ^a   King, Andrew G ^b   Levin, Robert ^b   Campochiaro, Peter A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL AVAILABILITY; CHOROID; CHOROIDAL NEOVASCULARIZATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETINA; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 65249175197     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.27     Document Type: Article

References (24)

1. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41 (10):3158-3164.
2. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental cho- roidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120(3):338-346.
3. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
4. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
5. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman MS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-1047.
6. Nguyen QD, Shah SM, Tatlipinar S, Do DV, Van Anden E, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol. 2005;89(10):1368-1370.
7. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113 (10):1695.e1-1705.e6.doi:10.1016/j.ophtha.2006. 05.064.
8. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina. 2006;26(8):960-963.
9. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-390.
10. Nguyen QD, Shah SM, Hafiz G, et al. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age- related macular degeneration. Am J Ophthalmol. 2008;145(2):257-266.
11. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for cho- roidal neovascularisation associated with pathological myopia. BrJOphthalmol. 2007;91(2):161-165.
12. Lindblom P, Gerhardt H, Liebner S, et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003;17(15):1835-1840.
13. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamiccor- relation from mouse to human with pazopanib, a multikinase angiogenesis in- hibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6(7):2012-2021.
14. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998; 153(5):1641-1646.
15. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188(2):253-263.
16. Ueno S, Pease ME, Wersinger DMB, et al. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol. 2008;217(1):13-22.
17. Seo M-S, Okamoto N, Vinores MA, et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. AmJPathol. 2000;157(3):995-1005.
18. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol. 1985;103(4):576-579.
19. Bergers G, Song S, Meyer-Morse N, Bersland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287-1295.
20. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol. 2006;168(6): 2036-2053.
21. Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1- alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther. 2006;5(6):1415-1422.
22. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184(3):275-284.
23. Hackett SF, Wiegand SJ, Yancopoulos G, Campochiaro P. Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol. 2002;192(2):182- 187.
24. Oshima Y, Deering T, Oshima S, et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol. 2004;199(3): 412-417.